Is 3′-deoxy-3′- [ 18F] fluorothymidine ([ 18F]-FLT) the next tracer for routine clinical PET after R [ 18F]-FDG?;La 3′-déoxy-3′-[ 18F] fluorothymidine ([ 18F]-FLT) est-elle le prochain traceur utilisé en routine pour la TEP après le [ 18F]-FDG?

Bulletin du Cancer

Volumn 92, Issue 9, 2005, Pages 789-798

  Couturier, Olivier ^a   Leost, Françoise ^a   Campone, Mario ^b   Carlier, Thomas ^a   Chatal, Jean François ^a   Hustinx, Roland ^c  

^a INSERM   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cancer imaging; Fluorinated tracers; Fluorothymidine; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE; 3' FLUOROTHYMIDINE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; THYMIDINE KINASE 1; TRACER; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIAGNOSTIC AGENT; FLUORINE;

CANCER; CANCER DIAGNOSIS; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DNA SYNTHESIS; DRUG DISTRIBUTION; DRUG UPTAKE; ENZYME ACTIVITY; EVALUATION; HUMAN; IMAGE ANALYSIS; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE CANCER; REVIEW; ANIMAL; METABOLISM; METHODOLOGY; NEOPLASM; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SYNTHESIS;

ANIMALS; DIDEOXYNUCLEOSIDES; FLUORINE RADIOISOTOPES; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 26844503208     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Senekowitsch-Schmidtke R, Rüth F, Bernatz S. Radiolabeled thymidine: a sensitive tracer for early tumor response and recurrence after irradiation. J Nucl Med 1999; 40: 1702-5.
2. Eary J, Mankoff D, Spence A, et al. 2-[C-11] thymidine imaging of malignant brain tumors. Cancer Res 1999; 59: 615-21.
3. Martiat P, Ferrant A, Labar D, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 1988; 29: 1633-7.
4. Shields A, Mankoff D, Link J, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39: 1757-62.
5. Van Eijkeren ME, De Schryver A, Goethals P, et al. Measurement of short-term 11C-thymidine activity in human head and neck tumours using positron emission tomography (PET). Acta Oncol 1992; 31: 539-43.
6. Vander Borght T, Pauwels S, Lambotte L, et al. Brain tumor imaging with PET and 2-[carbon-11] thymidine. J Nucl Med 1994; 25: 974-82.
7. Tjuvajev J, Maruki A, Ginos J, et al. Iododeoxyuridine (IUDR) uptake and retention as a mesure of tumor growth. J Nucl Med 1993; 34: 1152-61.
8. Tjuvajev J, Macapinlac H, Daghighian F, et al. Imaging of the brain tumor proliferative activity with [131I] iododeoxyuridine. J Nucl Med 1994; 35: 1407-17.
9. Blasberg R, Roelcke U, Weinreich B, et al. Imaging brain tumor proliferative activity with [124I] iododeoxyuridine. Cancer Res 2000; 60: 624-35.
10. Mankoff DA, Shields AF, Graham MM, et al. Kinetic analysis of 2-[carbon-11] thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 1998; 39: 1043-55.
11. Nimmagadda S, Mangner TJ, Muzik O, et al. Metabolic studies of F-18-FBAU in dogs: a PET tracer for DNA synthesis. J Nucl Med 2002; 43: 94.
12. Wang H, Oliver P, Nan L, et al. Radiolabeled 2′-fluorodeoxyuracil- beta-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-beta-D- arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemother Pharmacol 2002; 49: 419-24.
13. Flexner C, van der Horst C, Jacobson MA, et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and anti-retroviral activity in two concentration-controlled trials. J Infect Dis 1994; 170: 1394-403.
14. Wilson IK, Chatterjee S, Wolf W. Synthesis of 3′-fluoro-3′- deoxythymidine and studies of its 18F-radiolabeling, as a tracer for the noninvasive monitoring of the biodistribution of drugs against AIDS. J Fluorine Chem 1991; 55: 283-9.
15. Grierson J, Shields AF, Eary JF. Development of a radiosynthesis for 3′-[F-18] fluoro-3′-deoxynucleosides. J Labelled Compound Radiopharmaceuticals 1997; 40: 60-2.
16. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′-[(18) F] fluorothymidine: [(18)F] FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000; 27: 143-56.
17. Martin S, Eisenbarth J, Wagner-Utermann U, et al. [18F] FLT: 18F labeling of 3-Boc-1-(2-deoxy-3-O-nosyl-5-O-trityl-b-D-lyxofuranosyl) thymine and other thymine derivatives. J Nucl Med 2000: 41.
18. Martin S, Eisenbarth J, Wagner-Utermann U, et al. A new precursor for the radiosynthesis of [18F] FLT. Nucl Med Biol 2002; 29: 263-73.
19. Yun M, Oh SJ, Ha HJ, et al. High radiochemical yield synthesis of 3′-deoxy-3′-[18F] fluorothymidine using (5′-O-dimethoxytrityl- 2′-deoxy-3′-O-nosyl-beta-D-threo pentofuranosyl) thymine and its 3-N-BOC-protected analogue as a labeling precursor. Nucl Med Biol 2003; 30: 151-7.
20. Oh SJ, Mosdzianowski C, Chi OY, et al. Fully automated synthesis system of 3′-deoxy-3′-[18F] fluorothymidine. Nucl Med Biol 2004; 31: 803-9.
21. Belt J, Marina N, Phelps O, et al. Nucleoside transport in normal and neoplastic tells. Adv Enzyme Regal 1993; 33: 235-52.
22. Plagemann PG, Richey DP, Zylka JM, et al. Thymidine transport by Novikoff rat hepatoma cells synchronized by double hydroxyurea treatment. Exp Cell Res 1974; 83: 303-10.
23. Schwartz JL, Tamura Y, Jordan R, et al. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs J Nucl Med 2003; 11: 2027-32.
24. Toyohara J, Waki A, Takamatsu S, et al. Basis of FLT as cell proliferation marker: comparative uptake studies with [3H] thymidine and [3H] arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002; 29: 281-7.
25. Lu L, Samuelsson L, Bergstrom M, et al. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med 2002; 43: 1688-98.
26. Wagner M, Seitz U, Buck A, et al. 3′-[18F] fluoro-3′- deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003; 63: 2681-7.
27. Seitz LJ, Wagner M, Neumaier B, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F] fluoro-3′-deoxythymidine ([(18)F] FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002; 29: 1171-81.
28. Sundseth R, Joyner SS, Moore JT, et al. The anti-human immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob Agents Chemother 1996; 40: 331-5.
29. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1992; 36: 808-18.
30. Grierson JR, Schwartz JL, Muzi M, et al. Metabolism of 3′-deoxy-3′-[F-18] fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol 2004; 31: 829-37.
31. Rasey J, Grierson J, Wiens L, et al. Uptake of labeled FLT correlates with thymidine kinase (TK1) activity in human tumor cells. J Nucl Med 2000; 41 (suppl.): P36-P37.
32. Barthel H, Perumal M, Latigo J, et al. The uptake of 3′-deoxy- 3′-[(18)F] fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005; 32: 257-63.
33. Sorensen P, Wintersberger E. Sp1 and NF-Y are necessary and sufficient for growth-dependent regulation of the hamster thymidine kinase promoter. J Biol Chem 1999; 274: 30943-9.
34. Bartrek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Current Opin Cell Biol 1996; 8: 805-14.
35. Ewen M. The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev 1994; 13: 45-66.
36. Sherr C. D-type cyclins. Trend Biol Sci 1995; 20: 187-90.
37. Sherr C, Roberts J. Inhibitors of mammalian G1 cycline-dependent kinases. Genes Dev 1995; 9: 1149-63.
38. Weinberg R. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-30.
39. Buchmann I, Neumaier B, Schreckenberger M, et al. [18F] 3′-deoxy-3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations: a pilot study. Cancer Biother Radiopharm 2004; 19: 436-42.
40. Hengstchlager M, Hengstshlager-Ottnad E, Oliver P, et al. The role of p16 in the E2F-dependent thymidine kinase regulation. Oncogene 1996; 12: 1635-43.
41. Hengstchlager M, Knofler M, Mullner E, et al. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells J Biol Chem 1994; 269: 13836-42.
42. Hengstchlager M, Oliver P, Hengstshlager-Ottnad E, et al. Loss of the p16/MTS1 tumor suppressor gene causes E2F-mediated deregulation of essential enzymes of the DNA precursor metabolism. DNA Cell Biol 1996; 15: 41-51.
43. Coppock D, Pardee A. Control of thymidine kinase mRNA during the cell cycle. Mol Cell Biol 1987; 7: 2925-32.
44. Gross M, Merrill G. Regulation of thymidine kinase protein levels during myogenic withdrawal from the cell cycle is independent of mRNA regulation. Nucleic Acids Res 1988; 16: 11625-43.
45. Sherley J, Kelly T. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988; 263: 8350-8.
46. Ito M, Conrad S. Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells. J Biol Cbem 1990; 265: 6954-60.
47. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43: 1210-7.
48. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG J Nucl Med 2003; 44: 1426-31.
49. Wells P, Gunn RN, Alison M, et al. Assessment of proliferation in vivo using 2-[(11)C] thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 2002; 62: 5698-702.
50. Dittmann H, Dohmen BM, Kehlbach R, et al. Early changes in [18F] FLT uptake after chemotherapy : an experimental study. Eur J Nucl Med Mol Imaging 2002; 29: 1462-9.
51. Barthel H, Cleij MC, Collingridge DR, et al. 3′-deoxy-3′- [18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791-8.
52. Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004; 45: 519-25.
53. Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3′-deoxy- 3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004; 45: 1754-8.
54. Waldherr C, Mellinghoff IK, Tran C, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F- fluorothymidine PET. J Nucl Med 2005; 46: 114-20.
55. Kubota R, Kubota K, Yamada S, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-80.
56. Brown RS, Leung JY, Fisher SJ, et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995; 36: 1854-61.
57. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D- glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nuclear Med 1993; 34: 773-9.
58. Lewis P, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-9.
59. Minn H, Clavo AC, Grenman R, et al. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nuclear Med 1995; 36: 252-8.
60. Patz Jr. EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-90.
61. Wilmore DW, Aulick LH, Mason AD, et al. Influence of the burn wound on local and systemic responses to injury. Ann Surg 1977; 186: 444-58.
62. Sugawara Y, Gutowski TD, Fisher SJ, et al. Uptake of positron emission tomography tracers in experimental bacterial infections: a comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, 67Gacitrate, and 125I-HSA. Eur J Natl Med 1999; 26: 333-41.
63. Scharko AM, Perlman SB, Hinds P, et al. Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques. Proc Natl Acad Sci USA 1996; 93: 6425-30.
64. Wahl RL, Fisher SJ. A comparison of FDG, L-methionine and thymidine accumulation into experimental infections and reactive lymph nodes. J Nucl Med 1993; 34: 104P.
65. Van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of (18) F-FLT and (18) F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004; 45: 695-700.
66. Carter EA, McKuster K, Syed S, et al. Comparison of (FLT)-F-18 with (18) FDG for differentiation between tumor and focal sites of infection in rats. J Nuclear Med 2002; 43: 1074.
67. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nature Med 1998; 4: 1334-6.
68. Vesselle H, Grierson J, Peterson LM, et al. 18F-fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 2003; 44: 1482-8.
69. Buck AK, Schirrmeister H, Hetzel M, et al. 3-deoxy-3- [18] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62: 3331-4.
70. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003; 52: 1602-6.
71. Visvikis D, Francis D, Mulligan R, et al. Comparison of methodologies for the in vivo assessment of (18) FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 2004; 25: 637-41.
72. Vesselle H. The biology of lung cancer- FDG and fluorothymidine PET. Academic Radiology 2004; 11: E27.
73. Halter G, Buck AK, Schirrmeister H, et al. [F] 3-deoxy-3′- fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[F]-fluoro-2-deoxy-d-glucose positron emission tomography in the workup of suspicious central focal lesions?. J Thorac Cardiovasc Surg 2004; 127: 1093-9.
74. Dittmaim H, Dohmen BM, Paulsen F, et al. [18F] FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30: 1407-12.
75. Cobben DC, Elsinga PH, Hoekstra HJ, et al. Is 18F-3′-fluoro- 3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med 2004; 45: 1677-82.
76. Francis DL, Visvikis D, Costa DC, et al. Potential impact of [18F] 3′-deoxy-3′-fluorothymidine versus [18F] fluoro-2-deoxy-D-glucose in positron emission tomography forcolorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30: 988-94.
77. Cobben DC, Jager PL, Elsinga PH, et al. 3′-18F-fluoro-3′- deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med 2003; 44: 1927-32.
78. Cobben DC, van der Laan BF, Maas B, et al. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med 2004; 45: 226-31.
79. Cobben DC, Elsinga PH, Suurmeijer AJ, et al. Detection and grading of soft tissue sarcomas of the extremities with (18) F-3′-fluoro-3′- deoxy-L-thymidine. Clin Cancer Res 2004; 10: 1685-90.
80. Choi SJ, Kim JS, Kim JH, et al. [(18)F] 3′-deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005; (in press).
81. Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with [(18)F] fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004; 31: 720-4.
82. Van Westreenen HL, Cobben DC, Jager PL, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 2005; 46: 400-4.
83. Shields AF, Dohmen BM, Mangner TJ, et al. Use of F-18-FLT for imaging gastrointestinal tumors. J Nucl Med 2001; 42: 108.
84. Dohmen BM, Shields AF, Dittmann H, et al. Use of (FFLT)-F-18 for breast cancer imaging. J Nuclear Med 2001; 42: 107.
85. Pio BS, Park CK, Satyamurthy N, et al. PET with fluoro-L-thymidine allows early prediction of breast cancer response to chemotherapy. J Nucl Med 2003; 44: 76P.
86. Couturier O, Bodet-Milin C, Cherel M, et al. Fluorinated tracers for imaging tumoral proliferation with positron emission tomography. Médecine Nucléaire 2004; 28: 371-5.
87. Couturier O, Chatal J-F, Hustinx R. Fluorinated analogs of nucleosides and fluorinated tracers of gene expression for positron emission tomography. Bull Cancer 2004; 91: 695-703.